CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...